| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Jun 2025 | 23 Jun 2025 |
| Intimation for appointment of Mr. Navin Kumar (DIN: 08778662) as an Additional Director (Non-Executive Independent Director) of the Company with effect from June 23, 2025. | ||
| Board Meeting | 26 May 2025 | 19 May 2025 |
| Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve the Audited Financial Results for the Quarter & Year ended March 31 2025. The Board of Directors of the Company in the Meeting held on May 26, 2025 has inter-alia considered and approved the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors of the Company, for the Quarter and Year ended March 31, 2025. (As Per BSE Announcement Dated on: 26/05/2025) | ||
| Board Meeting | 6 Feb 2025 | 28 Jan 2025 |
| BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve the Unaudited Financial Results for the Third Quarter ended December 31 2024 The Board of Directors in the meeting held on February 06, 2025 has inter-alia approved Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31,2024 along with the Limited Review Report (As per BSE Announcement Dated on 06/02/2025) | ||
| Board Meeting | 11 Nov 2024 | 4 Nov 2024 |
| The Board Meeting to be held on 11/11/2024 has been revised to 11/11/2024 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve the Unaudited Financial Results for the Second Quarter ended September 30 2024. The Board of Directors in the meeting held on 11/11/2024 has inter-alia approved Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30,2024 along with the Limited Review Report (As Per BSE Announcement dated on 11.11.2024) | ||
| Board Meeting | 13 Aug 2024 | 6 Aug 2024 |
| BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the Unaudited Financial Results for the First Quarter ended June 30 2024. The Board of Directors in the meeting held on 13/08/2024 has inter-alia approved i) Unaudited Financial Results of the Company for the Quarter ended June 30,2024 along with the Limited Review Report; ii) Fixed the date of Annual General Meeting (AGM), Book Closure Date and Cut-Off Date for the purpose of AGM. (As per BSE Announcement Dated on 13/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.